New process for the preparation of inverse latex of acrylamide-based polymers and composition comprising said latex

Abstract

An inverse latex including from 20% to 70% by weight and preferably from 25% to 50% by weight of a branched or crosslinked polyelectrolyte, characterized in that the polyelectrolyte is a copolymer of 2-acrylamido-2-methylpropanesulfonic acid partially or totally salified with acrylamide and optionally one or more monomers chosen from monomers containing a partially or totally salified weak acid function and/or from neutral monomers other than acrylamide, the production process including the control of the pH in the initial aqueous phase; Cosmetic, dermopharmaceutical or pharmaceutical composition including the inverse latex directly obtained by the process.

1 . A cosmetic, dermopharmaceutical or pharmaceutical composition comprising, as thickening and/or emulsifying compound at least one self-invertible latex comprising an oil phase, an aqueous phase, at least one emulsifying system of the water-in-oil (W/O) type, at least one emulsifying system of the oil-in-water (O/W) type, and from 20% to 70% by weight of a branched or crosslinked polyelectrolyte,
 wherein said polyelectrolyte is a copolymer (P) of acrylamide with 2-acrylamido-2-methylpropanesulfonic acid partially or totally salified in a form of a salt selected from the group consisting of a sodium salt, a potassium salt and an ammonium salt, and   wherein said self-invertable latex is obtained by a process comprising the following steps:   (a) preparing an aqueous phase (A) comprising acrylamide, 2-acrylamido-2-methylpropanesulfonic acid partially or totally salified in the form of a sodium salt, or of a potassium salt or of an ammonium salt, and, optionally, hydrophilic additives, said preparing of aqueous phase (A) comprising:   (i) forming a solution by placing in water, acrylamide, said optional hydrophilic additives and 2-acrylamido-2-methylpropanesulfonic acid in a form of a salt selected from the group consisting of a sodium salt, a potassium salt and an ammonium salt,   (ii) to said solution, adding free 2-acrlyamido-2-methylpropanesulfonic acid and an alkaline agent selected from the group consisting of sodium hydroxide, potassium hydroxide and aqueous ammonia, said free 2-acrlyamido-2-methylpropanesulfonic acid and said alkaline agent being added in alternating portions to said solution such that said solution has a pH that remains greater than 1 and less than 3, to obtain a first aqueous mixture A1 having a pH greater than 1 and less than 3, and   (iii) adjusting the pH of said first aqueous mixture A1 to a pH between 5 and 6.5 to obtain said aqueous phase (A) and adding a branching or crosslinking agent;   (b) emulsifying said aqueous phase (A), in an organic phase comprising a surfactant system of the water-in-oil (W/O) type, the oil intended to be present in the final composition, optionally a volatile oil, and optional hydrophobic additives, to form a water-in-oil emulsion (B), said water-in-oil emulsion (B) comprising monomers;   (c) polymerizing the monomers in said water-in-oil emulsion (B), said polymerizing being initiated by introducing a free-radical initiator into said emulsion (B), to form an inverse latex (L1) of said copolymer (P);   optionally, (d) concentrating by distillation of said inverse latex (L1) of said copolymer (P) until said volatile oil has been removed, to form an inverse latex (L2) of said copolymer (P); and   (e) introducing an emulsifying system of the oil-in-water (O/W) type at a temperature below 50° C., in said inverse latex (L1) of said copolymer (P), or optionally in said inverse latex (L2) of said copolymer (P), to form a self-invertible inverse latex (L3) of said copolymer (P).   
     
     
         2 . The cosmetic, dermopharmaceutical or pharmaceutical composition as defined in  claim 1 , wherein the polyelectrolyte comprises:
 between 60 mol % and 20 mol % of 2-acrylamido-2-methylpropanesulfonic acid monomer partially or totally salified in a form of a salt selected from the group consisting of a sodium salt, a potassium salt and an ammonium salt, and   between 40 mol % and 80 mol % of acrylamide monomer.   
     
     
         3 . The cosmetic, dermopharmaceutical or pharmaceutical composition as defined in  claim 2 , wherein the polyelectrolyte comprises:
 between 50 mol % and 30 mol % of 2-acrylamido-2-methylpropanesulfonic acid monomer partially or totally salified in a form of a salt selected from the group consisting of a sodium salt, a potassium salt and an ammonium salt, and   between 50 mol % and 70 mol % of acrylamide monomer.   
     
     
         4 . The cosmetic, dermopharmaceutical or pharmaceutical composition as defined in  claim 2 , wherein the polyelectrolyte is selected from the group consisting of:
 crosslinked copolymers of 2-acrylamido-2-methylpropanesulfonic acid partially salified in the form of the sodium salt and of acrylamide;   crosslinked copolymers of 2-acrylamido-2-methylpropanesulfonic acid partially salified in the form of the ammonium salt and of acrylamide; and   crosslinked copolymers of 2-acrylamido-2-methylpropanesulfonic acid partially salified in the form of the potassium salt and of acrylamide.   
     
     
         5 . The cosmetic, dermopharmaceutical or pharmaceutical composition as defined in  claim 1 , further comprising either dihydroxyacetone and lactic acid or gluconic acid, either dihydroxyacetone and at least one sunscreen agent, either dihydroxyacetone and at least a moisturizing agent, either dihydroxyacetone and caffeine.